-
Visier's Vee for Microsoft Copilot Named a Top 'HR Product of the Year' by HR Executive
22 Sep 2025 18:21 GMT
… competition, organized by HR Executive and HR Tech, is … everyone from C-suite executives to frontline managers to make …
About HR Executive
Established in 1987, HR Executive is the premier … Domino's Pizza, Experian, Amgen, eBay, and Ford Motor Company …
-
AstraZeneca-Amgen Tezspire recommended for approval in EU for chronic rhinosinusitis with nasal polyps
22 Sep 2025 15:43 GMT
Cambridge: AstraZeneca and Amgen's Tezspire (tezepelumab) has … symptom relief."
Ruud Dobber, Executive Vice President and President, BioPharmaceuticals …
-
<![CDATA[Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC]]>
23 Sep 2025 15:50 GMT
… Cancer Research Program
Chair, Breast Executive Committee
Sarah Cannon Research Institute … Biotechnology, ADC Therapeutics, AKESOBIO Australia, Amgen, Aravive, ArQule, Artios, Arvinas, AstraZeneca …
-
Tezspire recommended for EU approval in nasal polyps
23 Sep 2025 10:33 GMT
CHMP backs AstraZeneca and Amgen’s therapy for chronic rhinosinusitis
… , sustained symptom relief.”
Ruud Dobber, Executive Vice President and President, BioPharmaceuticals …
-
EMA committee recommends approval of Tezspire for chronic rhinosinusitis with nasal polyps
23 Sep 2025 08:33 GMT
… symptom relief."
Ruud Dobber, executive vice president and president, biopharmaceuticals … single-digit inventor royalty to Amgen. AstraZeneca continues to lead … governing bodies. Under the agreement, Amgen and AstraZeneca will jointly commercialise …
-
To Compete in Obesity, Late Entrants Invest Early in Manufacturing
23 Sep 2025 04:12 GMT
… manufacturing front too, with Amgen and Roche collectively investing … infrastructure. In December 2024, Amgen unveiled a $1 billion … commitment to the site. Amgen reported Phase II data … previously anticipated.”
The Roche executive said the new facility is …
-
Prurigo Nodularis market to exhibit growth at a CAGR of 23.2% (2020-2034), driven by strong uptake of DUPIXENT, recent approval of NEMLUVIO, promising JAK and OX40 inhibitors in the Pipeline, along with rising prevalence | DelveInsight
22 Sep 2025 22:58 GMT
… therapeutic alternatives, including rocatinlimab (Amgen/Kyowa Kirin), … . These include rocatinlimab (Amgen/Kyowa Kirin), … Prurigo Nodularis Companies
Incyte, Amgen, Kyowa Kirin, Celldex Therapeutics … 2
Report Introduction
3
Executive Summary
4
Key …
-
ArriVent Appoints Brent S. Rice as Chief Commercial Officer
22 Sep 2025 20:05 GMT
… Yao, Chairman and Chief Executive Officer of ArriVent. “We … growth. We believe his executive leadership experience will position … patients access.” An experienced executive leader, Brent brings cross- … spent 18 years at Amgen in roles of increasing …
-
Kidney failure risk higher for adults with diabetes, low eGFR
22 Sep 2025 20:00 GMT
… . Tuttle, MD, FASN, FACP, FNKF, executive director for research at Providence … Xeris; and research funding from Amgen, Boehringer Ingelheim, Corcept, Lilly, Merck …
-
Alnylam Pharma joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine
20 Sep 2025 06:31 GMT
… of the alliance, joining AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb … ," said Leeland Ekstrom, chief executive officer of NashBio. "Additional …
About
© 1995-2025